Liu Rui, Wang Xiao-Hua, Liu Li, Zhou Qiang
Department of Oncology, Suining Central Hospital, Suining, China.
Asian Pac J Cancer Prev. 2012;13(7):3109-12. doi: 10.7314/apjcp.2012.13.7.3109.
Many studies have focused on possible associations between the glutathione S-transferase M 1 (GSTM1) null genotype and risk of renal cell carcinoma (RCC), but the impact remains unclear owing to obvious inconsistencies among the findings. The present study aimed to quantify the strength of any association in a meta-analysis.
We searched the PubMed, Embase and CBM databases for studies concerning the association between the GSTM1 null genotype and risk of RCC. We estimated the summary odds ratio (OR) with its 95% confidence intervals (95% CI) to assess the association.
The meta-analysis showed the GSTM1 null genotype was not associated with risk of RCC overall (OR = 1.04, 95% CI 0.92-1.18, P = 0.501). For Caucasians, the GSTM1 null genotype was also not associated with risk of RCC (OR = 1.02, 95% CI 0.90-1.16, P = 0.761). The cumulative meta-analyses showed a trend of no obvious association between GSTM1 null genotype and risk of RCC as information accumulated. Sensitivity analyses by omitting those studies also did not materially alter the overall combined ORs. No evidence of publication bias was observed.
Meta-analyses of available data show that the GSTM1 null genotype is not significantly associated with risk of renal cell carcinoma.
许多研究聚焦于谷胱甘肽S-转移酶M1(GSTM1)无效基因型与肾细胞癌(RCC)风险之间可能存在的关联,但由于研究结果明显不一致,其影响仍不明确。本研究旨在通过荟萃分析量化任何关联的强度。
我们在PubMed、Embase和中国生物医学文献数据库中检索关于GSTM1无效基因型与RCC风险关联的研究。我们估计汇总比值比(OR)及其95%置信区间(95%CI)以评估该关联。
荟萃分析表明,总体上GSTM1无效基因型与RCC风险无关(OR = 1.04,95%CI 0.92 - 1.18,P = 0.501)。对于高加索人,GSTM1无效基因型也与RCC风险无关(OR = 1.02,95%CI 0.90 - 1.16,P = 0.761)。累积荟萃分析表明,随着信息积累,GSTM1无效基因型与RCC风险之间无明显关联的趋势。通过剔除这些研究进行的敏感性分析也未实质性改变总体合并OR值。未观察到发表偏倚的证据。
对现有数据的荟萃分析表明,GSTM1无效基因型与肾细胞癌风险无显著关联。